[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-355519-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-355519-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","seomgemcadttd-clinical-guideline-for-the-diagnosis-and-treatment-of-esophageal-cancer-update-2025","SEOM–GEMCAD–TTD clinical guideline for the diagnosis and treatment of esophageal cancer (update 2025)","","Esophageal cancer is an aggressive disease and the seventh-leading cause of cancer death, comprising two histologically distinct entities: squamous cell carcinoma and adenocarcinoma. Their epidemiology and molecular differences drive different responses to novel therapies, requiring independent management strategies. Outcomes improve when multidisciplinary treatment is applied, and advances in targeted approaches, including immunotherapy, have enhanced patient results. This updated Spanish guideline summarizes current evidence and available therapeutic options.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/seomgemcadttd-clinical-guideline-for-the-diagnosis-and-treatment-of-esophageal-cancer-update-2025/355519/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/seomgemcadttd-clinical-guideline-for-the-diagnosis-and-treatment-of-esophageal-cancer-update-2025/355519.png","ImageObject",300,407,{"name":42,"@type":43},"Jordan Avery","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why must squamous cell carcinoma and adenocarcinoma of the esophagus be treated independently?","Question",{"text":63,"@type":64},"They represent two different diseases distinguished by histology, with distinct epidemiology and molecular profiles. These differences explain their different responsiveness to novel treatments.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do multidisciplinary strategies affect outcomes in esophageal cancer?",{"text":68,"@type":64},"Improved outcomes are obtained when a multidisciplinary therapeutic strategy is utilized. This supports integrated decision-making across care disciplines.",{"name":70,"@type":61,"acceptedAnswer":71},"What role do targeted therapies and immunotherapy play in recent improvements?",{"text":72,"@type":64},"The introduction of targeted therapies, including immunotherapy, has markedly improved patient outcomes. The guideline update summarizes these current available therapies.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},355519,1790479879,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145},1099523882367,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Clinical and Translational Oncology (2026) 28:1595–1609  \n[https://doi.org/10.1007/s12094-026-04291-y](https://doi.org/10.1007/s12094-026-04291-y)  \nSEOM–GEMCAD–TTD clinical guideline for the diagnosis and treatment of esophageal cancer (update 2025)  \nAna Fernández‑Montes1 · Julia Alcaide2 · Ana Belén Custodio3 · Lourdes Fernández Franco4 · Javier Gallego Plazas5 · Carlos Gómez‑Martín6 · Paula Richart6,7 · Fernando Rivera8 · Maria Alsina9  \nReceived: 9 February 2026 / Accepted: 10 February 2026 / Published online: 5 March 2026 © The Author(s) 2026  \nAbstract  \nEsophageal cancer represents an aggressive disease positioned as the seventh-leading cause of death from cancer. Esophageal cancer comprises two different diseases that should be distinguished by histology, i.e., squamous cell carcinoma andadenocarcinoma. The epidemiology and molecular differences between these two entities explain their different responsiveness to novel treatments which should be treated independently. The improvement in outcomes of patients with esophageal cancer are obtained when a multidisciplinary therapeutic strategy is utilized. The introduction of targeted therapies including immunotherapy has markedly improved patient outcomes. We present an updated version of the Spanish esophageal cancer guidelines, summarizing the current evidence and available therapies for the treatment of esophageal cancer.  \nKeywords Esophageal cancer · Squamous cell carcinoma · Adenocarcinoma · Diagnosis · Treatment  \nIntroduction  \nEsophageal cancer is a major public health problem, being the eleventh most common cancer worldwide and the seventh leading cause of death from cancer, with a 5-year  \n* Maria Alsina [malsinamaqued@gmail.com](malsinamaqued@gmail.com)  \nAna Fernández-Montes  \n[afm1003@hotmail.com](afm1003@hotmail.com)  \nJulia Alcaide  \n[julia.alcaide.sspa@juntadeandalucia.es](julia.alcaide.sspa@juntadeandalucia.es)  \nAna Belén Custodio  \n[anabcustodio@gmail.com](anabcustodio@gmail.com)  \nLourdes Fernández Franco  \n[lourdesfernandezfranco85@gmail.com](lourdesfernandezfranco85@gmail.com)  \nJavier Gallego Plazas  \n[j.gallegoplazas@gmail.com](j.gallegoplazas@gmail.com)  \nCarlos Gómez-Martín  \n[cgomezm@seom.org](cgomezm@seom.org)  \nPaula Richart  \n[paularichart@gmail.com](paularichart@gmail.com)  \nFernando Rivera  \n[fernando.rivera@scsalud.es](fernando.rivera@scsalud.es)  \n1 Medical Oncology Department, Complexo Hospitalario Universitario de Ourense, Ourense, Spain  \nsurvival rate of only 15–20%[1] . According to the report“Cancer figures in Spain 2025” published by SEOM, 1883 new cases of esophageal cancer are estimated for this year [2] . Of note, 70% of all cases of esophageal cancer occur in men [1] . The survival rate of esophageal cancer in Spain  \n2 Medical Oncology Department, Regional University Hospital of Malaga, IBIMA-BIONAND Platform, Málaga, Spain  \n3 Medical Oncology Department, Hospital Universitario la Paz, CIBERONC CB16/12/00398, Madrid, Spain  \n4 Medical Oncology Department, Hospital Virgen de la Salud, Toledo, Spain  \n5 Medical Oncology Department, Hospital General Universitario de Elche, Elche, Alicante, Spain  \n6 Gastrointestinal Cancer Unit, Medical Oncology Division, 12 de Octubre University Hospital, Madrid, Spain  \n7 Medical Oncology Department, Hospital Universitari IPolitècnic la Fe, Valencia, Spain  \n8 Medical Oncology Department, Hospital Universitario Marqués de Valdecilla and Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain  \n9 Medical Oncology Department, Hospital Universitario de Navarra (HUN), Navarrabiomed-Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain  \nvaries depending on gender, with survival rates for men increasing by 35% and in women decreasing by 9% from 2002–2007 to 2008–2013 [2] .  \nThere are two main histological types of esophageal cancer: squamous cell carcinoma (SCC), which makes up 85% of new cases globally and is located predominantly in the upper and mid-esoph","cbCaij7VbLHDc8WA","https://ap.wps.com/l/cbCaij7VbLHDc8WA","pdf",1065343,15,"English","# Abstract\n# Keywords\n# Introduction\n## Epidemiology and survival\n## Histological types and trends\n## Risk factors\n## Molecular features","[{\"question\":\"Why must squamous cell carcinoma and adenocarcinoma of the esophagus be treated independently?\",\"answer\":\"They represent two different diseases distinguished by histology, with distinct epidemiology and molecular profiles. These differences explain their different responsiveness to novel treatments.\"},{\"question\":\"How do multidisciplinary strategies affect outcomes in esophageal cancer?\",\"answer\":\"Improved outcomes are obtained when a multidisciplinary therapeutic strategy is utilized. This supports integrated decision-making across care disciplines.\"},{\"question\":\"What role do targeted therapies and immunotherapy play in recent improvements?\",\"answer\":\"The introduction of targeted therapies, including immunotherapy, has markedly improved patient outcomes. The guideline update summarizes these current available therapies.\"}]","SEOM–GEMCAD–TTD clinical guideline for the diagnosis and treatment of esophageal cancer (update 2025) | PDF",1790119593,38]